Capital Fund Management (CFM)’s Amicus Therapeutics FOLD Stock Holding History

Capital Fund Management (CFM)’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-762,698	Closed	-$4.37M	–	2532
2025 Q2	$4.37M	Buy	762,698 +450,137	+144%	+$2.91M	0.01%	1229
2025 Q1	$2.55M	Buy	312,561 +251,134	+409%	+$2.32M	0.01%	1315
2024 Q4	$579K	Sell	61,427 -25,344	-29%	-$263K	﹤0.01%	1883
2024 Q3	$927K	Buy	+86,771	New	+$945K	﹤0.01%	1706
2024 Q2	–	Sell	-69,431	Closed	-$818K	–	1970
2024 Q1	$818K	Buy	+69,431	New	+$888K	﹤0.01%	1765
2023 Q2	–	Sell	-47,072	Closed	-$522K	–	1746
2023 Q1	$522K	Buy	47,072 +8,250	+21%	+$102K	﹤0.01%	1440
2022 Q4	$474K	Buy	+38,822	New	+$437K	﹤0.01%	1284
2021 Q2	–	Sell	-24,864	Closed	-$246K	–	1503
2021 Q1	$246K	Buy	+24,864	New	+$385K	﹤0.01%	1219
2020 Q3	–	Sell	-14,337	Closed	-$216K	–	1269
2020 Q2	$216K	Buy	+14,337	New	+$175K	﹤0.01%	966

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital Fund Management (CFM)'s FOLD Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 762,698 shares — an estimated $4.37M sold.

Capital Fund Management (CFM) first reported a position in FOLD in Q2 2020 and held it in 9 quarters. The position peaked at $4.37M in Q2 2025. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

Capital Fund Management (CFM) reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 762,698 Amicus Therapeutics shares in Q3 2025, an estimated $4.37M.
Capital Fund Management (CFM) first reported a position in Amicus Therapeutics in Q2 2020 and held it in 9 quarters.
Capital Fund Management (CFM)'s Amicus Therapeutics position peaked at $4.37M in Q2 2025.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.